Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial.

MLA

Greinacher A, et al. “Treatment of Severe Neurological Deficits with IgG Depletion through Immunoadsorption in Patients with Escherichia Coli O104:H4-Associated Haemolytic Uraemic Syndrome: A Prospective Trial.” Lancet, vol. 378, no. 9797, Sept. 2011, pp. 1166–73. EBSCOhost, https://doi.org/10.1016/S0140-6736(11)61253-1.

APA

Greinacher A, Friesecke S, Abel P, Dressel A, Stracke S, Fiene M, Ernst F, Selleng K, Weissenborn K, Schmidt BM, Schiffer M, Felix SB, Lerch MM, Kielstein JT, & Mayerle J. (2011). Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet, 378(9797), 1166–1173. https://doi.org/10.1016/S0140-6736(11)61253-1

Chicago

Greinacher A, Friesecke S, Abel P, Dressel A, Stracke S, Fiene M, Ernst F, et al. 2011. “Treatment of Severe Neurological Deficits with IgG Depletion through Immunoadsorption in Patients with Escherichia Coli O104:H4-Associated Haemolytic Uraemic Syndrome: A Prospective Trial.” Lancet 378 (9797): 1166–73. doi:10.1016/S0140-6736(11)61253-1.